The preeclampsia biomarkers soluble fms-like tyrosine kinase-1 and placental growth factor: current knowledge, clinical implications and future application
63
Citation
80
Reference
10
Related Paper
Citation Trend
Keywords:
Fetal growth
Bench to bedside
Diagnostic biomarker
Preeclampsia is a multisystem disorder of pregnancy that contributes to morbidity and mortality worldwide. Soluble FMS-like tyrosine kinase-1 (sFlt-1) is considered as an etiologic factor of endothelial damage in preeclampsia. Imbalance of sFlt-1 and PlGF could cause failure in trophoblastic invasion and physiological remodeling of spiral artery, and ultimately placental hypoxia. This study aimed to observe anti-angiogenic properties of black rice bran on preeclampsia through measurement of sFlt-1 and PIGF. Serum was collected from pregnant women at 28-34 weeks of gestational age with preeclampsia, and normal preeclampsia as control. Level sflt-1 and PGIF was quantified with enzyme linked immunosorbent assay (ELISA). Absorbance was read at 450 nm wavelength. Extract of black rice bran has anti-angiogenic properties by significantly decreasing sFlt-1 as well as increasing PIGF in preeclampsia-induced HUVEC. This makes black rice bran a promising agent which can be further used in preeclampsia treatment.
Spiral artery
Cite
Citations (2)
Abstract Objective To compare the prognostic performance of biomarkers soluble fms-like tyrosine kinase-1 (sFlt-1), Placental Growth Factor (PIGF), and sFlt-1/PIGF ratio as continuous values or as a binary cut-off of 38 for predicting preeclampsia (PE) within 7 days. Design Secondary analysis of a randomised clinical trial. Setting Oxford University Hospitals, Oxford, United Kingdom (UK). Population Pregnant women between 24 +0 to 37 +0 weeks of gestation with a clinical suspicion of preeclampsia. Main outcome Onset of preeclampsia within 7 days of the initial biomarker test. Methods Logistic regression model for onset of preeclampsia using: (i) sFlt-1 (ii) PIGF, (iii) sFlt-1/PIGF ratio (continuous), and (iv) sFlt-1/PIGF ratio as a cut-off above or below 38. Results Of the total 370 women, 42 (11.3%) developed PE within 7 days of screening. Models with sFlt-1 and sFlt-1/PIGF ratio (continuous) had greater overall performance than models with PIGF or with sFlt-1/PIGF ratio as a cut-off at 38 ( R 2 : sFlt-1 = 55%, PIGF = 38%, sFlt-1/PIGF ratio = 57%, sFlt-1/PIGF ratio as cut-off at 38 model = 46%). The discrimination performance was the highest in sFlt-1 and sFlt-1/PIGF ratio (continuous) (c-statistic, sFlt-1 = 0.94, sFlt-1/PIGF ratio (continuous) = 0.94) models compared to PIGF or sFlt-1/PIGF cut-off models (c-statistic, PIGF = 0.87, sFlt-1/PIGF cut-off = 0.89). Conclusion Models using continuous values of sFlt-1 only or sFlt-1/PIGF ratio had better predictive performance compared to a PIGF only or the model with sFlt-1/PIGF ratio as a cut-off at 38. Further studies based on a larger sample size are warranted to substantiate this finding.
Cite
Citations (13)
Log in or Register Subscribe to journalSubscribe Get new issue alertsGet alerts Enter your Email address: Wolters Kluwer Health may email you for journal alerts and information, but is committed to maintaining your privacy and will not share your personal information without your express consent. For more information, please refer to our Privacy Policy. Subscribe to eTOC Secondary Logo Journal Logo All Articles Images Videos Podcasts Blogs Advanced Search Toggle navigation Subscribe Register Login Articles & Issues Current IssuePrevious Issues Collections Obstetric Airway ManagementMaternal EmbolismRegional Anesthesia for Cesarean SectionGeneral Anesthesia for Cesarean SectionAnalgesia for LaborObstetric HemorrhagePre-Eclampsia/EclampsiaPharmacologyTraumaInfection and SepsisMaternal ObesityMaternl Morbidity and MortalityNeonatal Morbidity and MortalityObstetric ComplicationsAnesthetic ComplicationsNon-Obstetric Maternal DiseaseCritical CareDrug Abuse in PregnancyEthicsSystems Based Practice For Authors Information for AuthorsLanguage Editing Services Journal Info About the JournalEditorial BoardAdvertisingOpen AccessSubscription ServicesReprintsRights and Permissions All Articles Images Videos Podcasts Blogs Advanced Search
Login
Cite
Citations (30)
Cite
Citations (0)
Log in or Register Subscribe to journalSubscribe Get new issue alertsGet alerts Enter your Email address: Wolters Kluwer Health may email you for journal alerts and information, but is committed to maintaining your privacy and will not share your personal information without your express consent. For more information, please refer to our Privacy Policy. Subscribe to eTOC Secondary Logo Journal Logo All Articles Images Videos Podcasts Blogs Advanced Search Toggle navigation Subscribe Register Login Articles & Issues Current IssuePrevious Issues Collections Obstetric Airway ManagementMaternal EmbolismRegional Anesthesia for Cesarean SectionGeneral Anesthesia for Cesarean SectionAnalgesia for LaborObstetric HemorrhagePre-Eclampsia/EclampsiaPharmacologyTraumaInfection and SepsisMaternal ObesityMaternl Morbidity and MortalityNeonatal Morbidity and MortalityObstetric ComplicationsAnesthetic ComplicationsNon-Obstetric Maternal DiseaseCritical CareDrug Abuse in PregnancyEthicsSystems Based Practice For Authors Information for AuthorsLanguage Editing Services Journal Info About the JournalEditorial BoardAdvertisingOpen AccessSubscription ServicesReprintsRights and Permissions All Articles Images Videos Podcasts Blogs Advanced Search
Login
Logo (programming language)
Cite
Citations (7)
Fetal growth
Cite
Citations (0)
Placental growth factor (PlGF), total soluble fms-like tyrosine-kinase 1 (sFlt-1) and its placental-specific variant, sFlt-1 e15a show promise for the prediction and diagnosis of pre-eclampsia. Limited data exist regarding their stability to inform clinical translation. This study describes the degradation of PlGF, sFlt-1 and sFlt-1 e15a within maternal serum and plasma during the 3rdtrimester of pregnancy. With consent, whole blood was collected from five participants and refrigerated at 4°C. Whole blood was then centrifuged following 1, 4, 8, 24 and 48 hours at 4°C for isolation of plasma and serum samples. PlGF and sFlt-1 were quantified using the B.R.A.H.M.S Kryptor Compact PLUS. sFlt-1 e15a was quantified using a custom enzyme-linked immunosorbent assay (ELISA). PlGF, sFlt-1 and sFlt-1 e15a are all stable in serum at 4 °C for up to 48 hours, with no statistically significant change throughout time (p = 0.837, p = 0.134, and p = 0.551 respectively). Likewise, PlGF, sFlt-1 and sFlt-1 e15a are stable in plasma at 4 °C for up to 48 hours, with no statistically significant change throughout time (p = 0.891, p = 0.651, and p = 0.428 respectively). Serum and plasma performed equally well to quantify PlGF and sFlt-1, and serum performed marginally better for sFlt-1 e15a. Blood samples collected for PlGF, sFlt-1 and sFlt-1 e15a analysis can be stored at 4°C for at least 48 hours before processing without impacting on analyte results. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Cite
Citations (0)
Cite
Citations (9)
The soluble fms-like tyrosine kinase (sFlt-1)/placental growth factor (PlGF) ratio seems to predict early-onset-preeclampsia (PE) and severe PE accurately. We tested if changes of sFlt-1, PIGF and sFlt-1/PIGF ratio directly before and after delivery are able to identify women at risk of complicated puerperal course in women delivering above 34 weeks of gestation.
Cite
Citations (0)
Objective To determine the predictive value of plasma soluble fms-like tyrosine kinase 1 (sFlt-1) and placental growth factor (PlGF) ratio for detection of preeclampsia in elderly gravida at 16–18 weeks of gestation and to identify whether abnormalities of this ratio are associated with any other pregnancy complications or not.Methods Blood samples of 300 cases were collected. Plasma sFlt-1 and PlGF levels were measured using an automated immunoassay.Results Sensitivity and specificity for plasma sFlt-1/PlGF ratio above 9.8 for preeclampsia prediction were 85.7% and 61.2%, respectively. The sensitivity and specificity to predict early onset preeclampsia were 100% and 61.1%, respectively. Women with abnormal plasma sFlt-1/PlGF ratio were not associated with any other pregnancy complications.Conclusion sFlt-1/PlGF ratio at 16–18 weeks of gestation in elderly gravida has a high sensitivity for predicting preeclampsia, especially early onset preeclampsia.
Cite
Citations (7)